NEWSROOM

Boston Solar Named First US Partner for Energizer Solar, Pioneering Renewable Energy Solutions in the American Market

Boston Solar Named First US Partner for Energizer Solar, Pioneering Renewable Energy Solutions in the American Market

Boston, MA, January 2nd, 2024 – In a groundbreaking move that marks a significant milestone in the renewable energy sector, Boston Solar, a subsidiary of SinglePoint Inc. (CBOE: SING), a leader in solar energy solutions, has joined forces with Energizer Solar to launch Energizer Solar renewable energy solutions starting with the Energizer Solar home battery solution. Energizer Solar is a global powerhouse in energy products. Already highly successful in Australia, Germany and the UK, this...

read more
(CORRECTION): SPZI: Three New Fully Executed Commodity Contracts; Year to Date Total $90.2 Million

(CORRECTION): SPZI: Three New Fully Executed Commodity Contracts; Year to Date Total $90.2 Million

36.7 million value – JP Energy Global, wholly owned subsidiary of JP 3E Holdings, Inc., formerly Spooz Inc., executed three transactions for chicken paws Clearwater, FL., December 29, 2023 - JP Energy Global, PTE, LTD, a wholly owned subsidiary of JP 3E Holdings, Inc., formerly Spooz, Inc. (OTC: SPZI), is pleased to announce the execution of three commodity contracts totaling $36,774,000 for Grade A Chicken Paws. The previous announcement was for $53,460,000 for one fully executed contract....

read more
(CORRECTION): SPZI: Three New Fully Executed Commodity Contracts; Year to Date Total $90.2 Million

SPZI: Three New Fully Executed Commodity Contracts; Year to Date Total $90.2 Million

$36.7 million value – JP Energy Global, wholly owned subsidiary of JP 3E Holdings, Inc., formerly Spooz Inc., executed three transactions for chicken paws Clearwater, FL., December 29, 2023 - JP Energy Global, PTE, LTD, a wholly owned subsidiary of JP 3E Holdings, Inc., formerly Spooz, Inc. (OTC: SPZI), is pleased to announce the execution of three commodity contracts totaling $36,774,000 for Grade A Chicken Paws. The previous announcement was for $53,460,000 for one fully executed contract....

read more
PRISM MediaWire – Weekly Press Resume – Dec. 25 to Dec. 29, 2023

PRISM MediaWire – Weekly Press Resume – Dec. 25 to Dec. 29, 2023

New York, December 29, 2023 PRISM MediaWire - Weekly Press Resume Dec. 25 to Dec. 29, 2023 SS Innovations Announces Strategic Partnership with Surgical Lab for Distribution in Africa https://prismmediawire.com/ss-innovations-announces-strategic-partnership-with-surgical-lab-for-distribution-in-africa/ SPZI: $53.4 million fully executed commodity contract closed https://prismmediawire.com/spzi-53-4-million-fully-executed-commodity-contract-closed/ Rodedawg Intl. Ind, Inc. (OTC: RWGI) Acquires...

read more
Most Popular PRISM MarketView Articles in 2023

Most Popular PRISM MarketView Articles in 2023

New York, December 29, 2023 - 2023 was a year filled with significant developments in emerging stocks, featuring a wide range of topics from clinical updates and strategic partnerships to earnings reports. Notable stories include Oncocyte’s initiation of the FDA submission process for its kidney transplant monitoring test, SKYX’s partnership with Kichler, and Soluna’s robust Q3 earnings. The year also saw engaging discussions on unique topics like full moon trading, Thanksgiving strategies,...

read more
Microbot Medical is Set to Progress its Liberty Robotic System into Pivotal Clinical Trial; Shares soar 60%

Microbot Medical is Set to Progress its Liberty Robotic System into Pivotal Clinical Trial; Shares soar 60%

New York, December 28, 2023 - Microbot Medical Inc. (Nasdaq: MBOT) has completed its GLP pivotal pre-clinical study for the LIBERTY® Endovascular Robotic Surgical System. The study, adhering to FDA guidelines and using a porcine model, successfully met all its objectives, including conducting 96 robotic navigations by three interventional radiologists. This involved evaluating target vessels and surrounding tissues with the LIBERTY system controlling various intravascular catheterization...

read more
Enveric Biosciences Announces EB-003 as Lead Drug Candidate for Mental Health Disorders; Stock Jumps 37%

Enveric Biosciences Announces EB-003 as Lead Drug Candidate for Mental Health Disorders; Stock Jumps 37%

New York, December 28, 2023 - Enveric Biosciences (NASDAQ: ENVB), a biotechnology company specializing in developing novel treatments for mental health disorders, has named EB-003 as the lead candidate from its EVM301 Series. This series targets depression, anxiety, and addiction disorders. The selection of EB-003 is a key milestone for Enveric, transitioning the company from a discovery phase to a drug development phase. EB-003 is chosen for its potential to...

read more
SinglePoint Successfully Lists on Cboe; Welcomes Tony Thomas as New Board Member in Expansion of Board Bolstering Company’s Commitment to Strategic Growth in the Solar Sector

SinglePoint Successfully Lists on Cboe; Welcomes Tony Thomas as New Board Member in Expansion of Board Bolstering Company’s Commitment to Strategic Growth in the Solar Sector

Phoenix, AZ, December 28, 2023 - SinglePoint Inc. (Cboe: SING) (“SinglePoint'' or “the Company'') a provider in renewable energy, energy supply and healthy building solutions is delighted to announce the appointment of Tony Thomas to its Board of Directors. Mr. Thomas brings a wealth of experience and expertise in strategic advisory, investment, and board governance.   Mr. Thomas serves as a Managing Director and Head of the financial advisory and asset management practice of Harbor...

read more
PRISM Emerging MedDevices Mover Spotlight: Milestone Scientific Inc. (MLSS)

PRISM Emerging MedDevices Mover Spotlight: Milestone Scientific Inc. (MLSS)

New York, December 27, 2023 - Milestone Scientific Inc. (NYSE:MLSS) has established itself in the field of biomedical technology with its focus on advanced injection technologies for medical and dental applications. The company holds over 19 US patents and 133 foreign patents. Its dental product, the Single Tooth Anesthesia System (STA), has received FDA and CE marketing clearance in more than 50 countries. The STA system utilizes computer-assisted technology for precise and consistent...

read more
Immutep Advances Towards Phase III Trial for Lung Cancer Treatment with Positive Regulatory Feedback

Immutep Advances Towards Phase III Trial for Lung Cancer Treatment with Positive Regulatory Feedback

New York, December 27, 2023 - Immutep Limited (ASX: IMM; NASDAQ: IMMP), a trailblazing clinical-stage biotechnology company, has announced encouraging news from the Paul-Ehrlich-Institut (PEI), part of the Committee for Medicinal Products for Human Use (CHMP). This announcement marks a significant step forward in the company’s development of novel LAG-3 immunotherapies for cancer and autoimmune diseases. https://prismmarketview.com/companies/immutep-limited/#news Marc Voigt, CEO of Immutep...

read more

Contact Us

PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850